Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

Clinical and Molecular Profile of Duchenne Muscular Dystrophy (DMD): Case-Record Analysis From Uttar Pradesh, India

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Identification of LAMA2 Compound Heterozygous Variants: a Case Report

In a cohort of 961 clinically suspected Duchenne muscular dystrophy patients, 105 were diagnosed to have other muscular dystrophies (OMDs), with LGMD2E (variant SGCB c.544A>C) being the most common

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

[Genotype, Phenotype Analysis and Follow-Up Study on Patients with Duchenne/Becker Muscular Dystrophy].

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Screening of Duchenne Muscular Dystrophy (DMD) Mutations and Investigating Its Mutational Mechanism in Chinese Patients.

[Gene Mutation Spectrum Analysis of 170 Patients with Duchenne/Bayesian Muscular Dystrophy in Southwest of China].

A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China

Genetic Variation Analysis and Treatment Strategy of 20 Patients with Dystrophin Gene Mutations

Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies

Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing

Characteristics of Dystrophin Gene Mutations among Chinese Patients As Revealed by Multiplex Ligation–Dependent Probe Amplification

Identification of Two Rare Mutations C.1318g>a and C.6438+2t>g in a Chinese DMD Family As Genetic Markers

DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations

Identification of Two Novel Variants of the DMD Gene in Chinese Families with Duchenne Muscular Dystrophy

Patterns of dystrophin gene deletion in Egyptian Duchenne/Becker muscular dystrophy patients

Molecular Diagnosis of Duchenne Muscular Dystrophy Using Single NGS-Based Assay

[Genetic Testing and Prenatal Diagnosis of 671 Chinese Pedigrees Affected with Duchenne/Becker Muscular Dystrophy].